Raquel G Da Mata Selected Research

foralumab

1/2021	Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.
1/2021	Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raquel G Da Mata Research Topics

Disease

2	COVID-19 01/2021 - 01/2021
2	Pneumonia (Pneumonitis) 01/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

2	foralumabIBA 01/2021 - 01/2021
2	Monoclonal AntibodiesIBA 01/2021 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2021

Therapy/Procedure

2	Intranasal Administration 01/2021 - 01/2021